The present invention relates to quinazoline containing zinc-binding moietybased derivatives that have enhanced and unexpected properties as inhibitorsof epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their usein the treatment of EGFR-TK related diseases and disorders such as cancer. Thesaid derivatives may further act as HDAC inhibitors.